{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:25:56Z","timestamp":1780525556014,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP19\/00159, FI21\/00165, FI19\/00304, CM21\/00115"],"award-info":[{"award-number":["CP19\/00159, FI21\/00165, FI19\/00304, CM21\/00115"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020230","name":"Consejer\u00eda de Transformaci\u00f3n Econ\u00f3mica, Industria, Conocimiento y Universidades","doi-asserted-by":"publisher","award":["P20_00906"],"award-info":[{"award-number":["P20_00906"]}],"id":[{"id":"10.13039\/100020230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["GLD21_00096"],"award-info":[{"award-number":["GLD21_00096"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Data on SARS-CoV-2 mRNA vaccine immunogenicity in people living with human immunodeficiency virus (PLWH) and discordant immune response (DIR) are currently limited. Therefore, we compare the immunogenicity of these vaccines in DIR and immunological responders (IR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective cohort that enrolled 89 participants. Finally, 22 IR and 24 DIR were analyzed before vaccination (T<jats:sub>0<\/jats:sub>), one (T<jats:sub>1<\/jats:sub>) and six months (T<jats:sub>2<\/jats:sub>) after receiving BNT162b2 or mRNA-1273 vaccine. Additionally, 10 IR and 16 DIR were evaluated after a third dose (T<jats:sub>3<\/jats:sub>). Anti-S-RBD IgG, neutralizing antibodies (nAb), neutralization activity, and specific memory B cells were quantified. Furthermore, specific CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> responses were determined by intracellular cytokine staining and polyfunctionality indexes (Pindex).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At T<jats:sub>1<\/jats:sub>, all participants developed anti-S-RBD. 100% IR developed nAb compared to 83.3% DIR. Spike-specific B cells were detected in all IR and 21\/24 DIR. Memory CD4<jats:sup>+<\/jats:sup> T cells responded in 5\/9 IR and 7\/9 DIR, mainly based on the expression of IFN-\u03b3 and TNF-\u03b1, with a higher Pindex in DIR. Memory CD8<jats:sup>+<\/jats:sup> T cells responded in only four participants in each group. At T<jats:sub>2<\/jats:sub>, anti-S-RBD and nAb titers were higher in DIR than in IR. In both groups, there was an increase in specific B memory cells, higher in DIR. Six IR and five DIR maintained a specific memory CD4<jats:sup>+<\/jats:sup> response. Memory CD8<jats:sup>+<\/jats:sup> response was preserved in IR but was lost in DIR. In a multivariate linear regression analysis, receiving mRNA-1273 instead of BNT162b2 played a prominent role in the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data suggest that PLWH with DIR can mount an immune response similar to those with higher CD4<jats:sup>+<\/jats:sup>, provided they receive the mRNA-1273 vaccine instead of others less immunogenic.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1129753","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:25:35Z","timestamp":1678854335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered"],"prefix":"10.3389","volume":"14","author":[{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Saborido-Alconchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Trujillo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Serna-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Llaves-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Mu\u00f1oz-Muela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"P\u00e9rez-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mejias-Trueba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Guti\u00e9rrez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"B1","unstructured":"COVID-19 vaccine tracker and landscape"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917905","article-title":"Comparison of IgA, IgG, and neutralizing antibody responses following immunization with moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and sinopharm's COVID-19 vaccines","volume":"13","author":"Adjobimey","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115463","article-title":"Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U","volume":"386","author":"Dickerman","year":"2022","journal-title":"S. Veterans N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.03.069","article-title":"Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies","volume":"40","author":"Sughayer","year":"2022","journal-title":"Vaccine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab687","article-title":"Effectiveness of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines for preventing coronavirus disease 2019 hospitalizations in the united states","volume":"74","author":"Tenforde","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B7","volume-title":"European Centre for Disease Prevention and Control and the European Medicines Agency  update recommendations on additional booster doses of COVID-19 vaccines","year":"2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100287","article-title":"Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study","volume":"13","author":"Lombardi","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.07.031","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1","volume":"27","author":"Levy","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003135","article-title":"High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters","volume":"36","author":"Xu","year":"2022","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003300","article-title":"High seroconversion rate and SARS-CoV-2 delta neutralization in people with HIV vaccinated with BNT162b2","volume":"36","author":"Pourcher","year":"2022","journal-title":"AIDS"},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-022-00452-6","article-title":"Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy","volume":"7","author":"Brumme","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac089","article-title":"SARS-CoV-2 humoral and cellular immune responses of patients with HIV after vaccination with BNT162b2 mRNA COVID-19 vaccine in the tel-Aviv medical center","volume":"9","author":"Tau","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27629","article-title":"Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in bari, Italy","volume":"94","author":"Milano","year":"2022","journal-title":"J Med Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1009","article-title":"Differences in post-mRNA vaccination severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) concentrations and surrogate virus neutralization test response by human immunodeficiency virus (HIV) status and type of vaccine: A matched case-control observational study","volume":"75","author":"Spinelli","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.820126","article-title":"Impact on HIV-1 RNA levels and antibody responses following SARS-CoV-2 vaccination in HIV-infected individuals","volume":"12","author":"Portillo","year":"2021","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003166","article-title":"Impaired antibody response to COVID-19 vaccination in advanced HIV infection","volume":"36","author":"Hassold","year":"2022","journal-title":"AIDS"},{"key":"B21","doi-asserted-by":"publisher","first-page":"jiac229","DOI":"10.1093\/infdis\/jiac229","article-title":"People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses","volume":"2022","author":"Lapointe","year":"2022","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003161","article-title":"Safety and immunogenicity of SARS-CoV-2 vaccines in people with HIV","volume":"36","author":"Gonzalez de Aledo","year":"2022","journal-title":"AIDS"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.05.018","article-title":"Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV","volume":"28","author":"Corma-Gomez","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-021-01721-7","article-title":"Humoral response to SARS-CoV-2 vaccines in people living with HIV","volume":"50","author":"Noe","year":"2022","journal-title":"Infection"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac169","article-title":"Antibody response in immunocompromised patients after the administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine BNT162b2 or mRNA-1273: A randomized controlled trial","volume":"75","author":"Speich","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0156099","DOI":"10.1371\/journal.pone.0156099","article-title":"Discordant immune response with antiretroviral therapy in HIV-1: A systematic review of clinical outcomes","volume":"11","author":"Kelly","year":"2016","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001990","article-title":"Brief report: Response to hepatitis a virus vaccine in HIV-infected patients within a retrospective, multicentric cohort: Facing hepatitis a outbreaks in the clinical practice","volume":"81","author":"Neukam","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.03.029","article-title":"Response to a reinforced hepatitis b vaccination scheme in HIV-infected patients under real-life conditions","volume":"37","author":"Neukam","year":"2019","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.05.077","article-title":"Influenza vaccination for HIV-positive people: Systematic review and network meta-analysis","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.994173","article-title":"Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination","volume":"13","author":"Sistere-Oro","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1605","article-title":"Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC world health organization (WHO) clinical characterization protocol (UK): A prospective observational study","volume":"73","author":"Geretti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1339","article-title":"Characteristics, comorbidities, and outcomes in a multicenter registry of patients with human immunodeficiency virus and coronavirus disease 2019","volume":"73","author":"Dandachi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac238","article-title":"Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count","volume":"75","author":"Antinori","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac406","article-title":"Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PWH with poor immune reconstitution","volume":"226","author":"Benet","year":"2022","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003246","article-title":"Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV","volume":"36","author":"Chammartin","year":"2022","journal-title":"AIDS"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100178","article-title":"Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine","volume":"9","author":"Stumpf","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101326","article-title":"Comparison of moderna versus pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. veterans affairs healthcare system","volume":"45","author":"Ioannou","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B41","unstructured":"Spikevax. assessment report2021"},{"key":"B42","volume-title":"Comirnaty. assessment report","year":"2021"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4922","DOI":"10.1038\/s41467-022-32263-7","article-title":"Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV","volume":"13","author":"Vergori","year":"2022","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/vaccines10020303","article-title":"The effect of smoking on humoral response to COVID-19 vaccines: A systematic review of epidemiological studies","volume":"10","author":"Ferrara","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1129753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T04:25:40Z","timestamp":1678854340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1129753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2023.1129753"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1129753","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"1129753"}}